Checkpoint Therapeutics, INC Form 4 insider transactions

James F. Oliviero III, CEO, President, and Director of Checkpoint Therapeutics, Inc., acquired 1,660,000 shares of restricted common stock on May 24, 2024.

Michael Weiss, a director at Checkpoint Therapeutics, acquired 82,051 shares of common stock on May 14, 2024, through restricted stock grants.

Director Amit Sharma reports acquisition of 32,051 shares of Checkpoint Therapeutics common stock on May 14, 2024.

Barry M. Salzman, a director of Checkpoint Therapeutics, acquired restricted common stock on May 14, 2024, according to a Form 4 filing with the SEC.

Director Lindsay Rosenwald acquired shares of Checkpoint Therapeutics common stock on May 14, 2024, through grants of restricted stock.

Neil Herskowitz, a director of Checkpoint Therapeutics, acquired shares of common stock on May 14, 2024, as reported in a Form 4 filing with the SEC.

Christian Bechon, a director at Checkpoint Therapeutics, acquired 32,051 and 50,000 shares of common stock on May 14, 2024, with vesting schedules extending to 2029.

Fortress Biotech acquired 193,905 shares of Checkpoint Therapeutics common stock on March 20, 2024, as an equity fee related to a financing.

James Oliviero, CEO of Checkpoint Therapeutics, reports the sale of shares to cover tax obligations and a transfer of shares to an irrevocable trust for his children.

William Garrett Gray, CFO of Checkpoint Therapeutics, sold 2,035 shares of common stock on February 28, 2024, to cover tax obligations related to vesting restricted stock.